Sign Out
Effects on fertility: Fertility following the treatment of vincristine sulfate for malignant disease has not been studied in humans. Clinical reports of both male and female patients who have received multiple-agent chemotherapy that included vincristine indicate that azoospermia and amenorrhoea can occur in post pubertal patients. Recovery occurred many months after completion of chemotherapy in some, but not all, patients. When the same treatment is administered to prepubertal patients, permanent azoospermia and amenorrhoea are much less likely.
Use in pregnancy - Category D: Vincristine can cause foetal harm when administered to a pregnant woman. Vincristine sulfate can induce teratogenesis as well as embryo death with doses that are non-toxic to the pregnant animal. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while receiving this drug, she should be apprised of the potential hazard to the foetus. Women of childbearing potential should be advised to avoid becoming pregnant.
Use in lactation: It is not known whether vincristine is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions due to vincristine in breast-fed infants, a decision should be made either to discontinue breast-feeding or the vincristine therapy, taking into account the importance of the medicine to the mother.
